Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients

Medical Oncology

Volumn 31, Issue 3, 2014, Pages

  Huang, Yong ^a   Yu, Haijun ^a   Lei, Han ^a   Xie, Conghua ^a   Zhong, Yahua ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Colorectal neoplasms; Drug resistance; Fluorouracil; MMP7

Indexed keywords

FAS LIGAND; FLUOROURACIL; MATRILYSIN; TUMOR MARKER; ANTINEOPLASTIC ANTIMETABOLITE; MMP7 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; CANCER GRADING; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84892691559     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0824-0     Document Type: Article

References (22)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-8.
2. IMPACT: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939-44.
3. Johnston PG, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs. 2001;12(8):639-46.
4. Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via Fas signaling. P Natl Acad Sci USA. 1997;94(15):8144-9.
5. Houghton JA, Harwood FG, Gibson AA, Tillman DM. The Fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. Clin Cancer Res. 1997;3(12):2205-9.
6. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):101-17.
7. Yokoyama Y, Grunebach F, Schmidt SM, Heine A, Hantschel M, Stevanovic S, Rammensee HG, Brossart P. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res. 2008;14(17):5503-11.
8. Wadsworth SJ, Atsuta R, McIntyre JO, Hackett TL, Singhera GK, Dorscheid DR. IL-13 and TH2 cytokine exposure triggers matrix metalloproteinase 7-mediated Fas ligand cleavage from bronchial epithelial cells. J Allergy Clin Immunol. 2010;126(2):366-74, e361-68.
9. Strand S, Vollmer P, van den Abeelen L, Gottfried D, Alla V, Heid H, Kuball J, Theobald M, Galle PR, Strand D. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene. 2004;23(20):3732-6.
10. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61(2):577-81.
11. Almendro V, Ametller E, Garcia-Recio S, Collazo O, Casas I, Auge JM, Maurel J, Gascon P. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PLoS ONE. 2009;4(3):e4728.
12. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Mármol M, Gallardo E, Maria Augé J, Longarón R, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007;121(5):1066-71.
13. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18(1):136-47.
14. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041-7.
15. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-5.
16. Johnston PG, Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 2003;63(15):4602-6.
17. Yin A, Jiang Y, Zhang X, Luo H. Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. Med Oncol. 2010;27(2):397-405.
18. Zhang Y, Yuan J, Zhang HY, Simayi D, Li PD, Wang YH, Li F, Zhang WJ. Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells. Clin Exp Med. 2011;12:97.
19. Krammer PH, Eichhorst ST, Muerkoster S, Weigand MA. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res. 2001;61(1):243-8.
20. Aquino Esperanza JA, Aguirre MV, Aispuru GR, Lettieri CN, Juaristi JA, Alvarez MA, Brandan NC. In vivo 5-fluorouracil-[corrected]induced apoptosis on murine thymocytes: involvement of FAS, Bax and Caspase3. Cell Biol Toxicol. 2008;24(5):411-22.
21. Gallego R, Codony-Servat J, Garcia-Albeniz X, Carcereny E, Longaron R, Oliveras A, Tosca M, Auge JM, Gascon P, Maurel J. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr Relat Cancer. 2009;16(1):311-7.
22. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T. Gene expression profile can predict pathological response to preoperative chemoradiotherapy in rectal cancer. Cancer Genom Proteom. 2011;8(2):87-92.